{"nctId":"NCT00308581","briefTitle":"Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab","startDateStruct":{"date":"2006-04"},"conditions":["Crohn's Disease"],"count":539,"armGroups":[{"label":"Active 1","type":"EXPERIMENTAL","interventionNames":["Biological: Certolizumab pegol","Other: Placebo"]},{"label":"Active 2","type":"EXPERIMENTAL","interventionNames":["Biological: Certolizumab pegol"]}],"interventions":[{"name":"Certolizumab pegol","otherNames":["CDP870","Cimzia"]},{"name":"Certolizumab pegol","otherNames":["CDP870","Cimzia"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with Crohn's Disease\n* Previous treatment failure to Infliximab (intolerance and/or no response)\n\nExclusion Criteria:\n\n* Obstructive intestinal strictures\n* Recent bowel resection\n* Proctocolectomy or total colectomy\n* Current total parenteral nutrition\n* Short bowel syndrome\n* All concomitant diseases or pathological conditions that could interfere with Crohn's disease assessment or to be harmful for the well being of the patient\n* Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Response Status With Response Defined as at Least 100 Point Decrease in Crohn's Disease Activity Score (CDAI Score) From Baseline in the Induction Phase","description":"Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score) from baseline, otherwise there is a non-response.\n\nThe CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"334","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Status With Response Defined as at Least 100 Point Decrease in CDAI Score From Baseline in the Randomized Maintenance Phase","description":"Response is defined as at least 100 point decrease in CDAI score from baseline. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Induction Phase","description":"Response is defined as at least 70 points reduction in CDAI score. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"373","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Randomized Maintenance Phase","description":"Response is defined as at least 70 points reduction in CDAI score. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]}]},{"type":"SECONDARY","title":"Remission Status With Remission Defined as CDAI Score ≤ 150 in the Induction Phase","description":"Remission is defined as CDAI score ≤ 150. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"327","spread":null}]}]}]},{"type":"SECONDARY","title":"Remission Status With Remission Defined as CDAI Score ≤ 150 in the Randomized Maintenance Phase","description":"Remission is defined as CDAI score ≤ 150. The CDAI score is used to quantify the symptoms with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]}]},{"type":"SECONDARY","title":"CDAI Score at Week 2 of the Induction Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"241.53","spread":"97.03"}]}]}]},{"type":"SECONDARY","title":"CDAI Score at Week 4 of the Induction Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"220.87","spread":"101.05"}]}]}]},{"type":"SECONDARY","title":"CDAI Score at Week 6 of the Induction Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"187.81","spread":"103.34"}]}]}]},{"type":"SECONDARY","title":"CDAI Score at Week 8 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"175.62","spread":"94.08"},{"groupId":"OG001","value":"169.18","spread":"86.63"}]}]}]},{"type":"SECONDARY","title":"CDAI Score at Week 10 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"164.65","spread":"98.16"},{"groupId":"OG001","value":"162.86","spread":"88.66"}]}]}]},{"type":"SECONDARY","title":"CDAI Score at Week 12 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173.83","spread":"103.89"},{"groupId":"OG001","value":"163.78","spread":"96.19"}]}]}]},{"type":"SECONDARY","title":"CDAI Score at Week 14 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162.34","spread":"99.74"},{"groupId":"OG001","value":"158.68","spread":"90.76"}]}]}]},{"type":"SECONDARY","title":"CDAI Score at Week 16 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163.73","spread":"103.65"},{"groupId":"OG001","value":"156.05","spread":"90.49"}]}]}]},{"type":"SECONDARY","title":"CDAI Score at Week 18 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"153.38","spread":"95.65"},{"groupId":"OG001","value":"156.64","spread":"90.99"}]}]}]},{"type":"SECONDARY","title":"CDAI Score at Week 20 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162.79","spread":"112.53"},{"groupId":"OG001","value":"138.60","spread":"80.78"}]}]}]},{"type":"SECONDARY","title":"CDAI Score at Week 22 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128.13","spread":"85.34"},{"groupId":"OG001","value":"141.89","spread":"90.43"}]}]}]},{"type":"SECONDARY","title":"CDAI Score at Week 24 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135.49","spread":"99.92"},{"groupId":"OG001","value":"139.50","spread":"75.98"}]}]}]},{"type":"SECONDARY","title":"CDAI Score at Week 26 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"122.37","spread":"87.49"},{"groupId":"OG001","value":"131.41","spread":"79.52"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI Score at Week 2 of the Induction Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-66.57","spread":"85.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI Score at Week 4 of the Induction Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-87.63","spread":"93.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI Score at Week 6 of the Induction Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-120.33","spread":"90.81"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI Score at Week 8 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-133.35","spread":"85.90"},{"groupId":"OG001","value":"-137.70","spread":"75.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI Score at Week 10 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-145.16","spread":"90.76"},{"groupId":"OG001","value":"-145.26","spread":"76.97"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI Score at Week 12 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-134.51","spread":"91.52"},{"groupId":"OG001","value":"-145.17","spread":"78.88"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI Score at Week 14 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-145.54","spread":"86.85"},{"groupId":"OG001","value":"-144.08","spread":"86.34"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI Score at Week 16 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-141.90","spread":"98.56"},{"groupId":"OG001","value":"-144.89","spread":"83.81"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI Score at Week 18 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-150.38","spread":"88.68"},{"groupId":"OG001","value":"-144.66","spread":"85.43"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI Score at Week 20 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-139.98","spread":"104.52"},{"groupId":"OG001","value":"-162.85","spread":"80.93"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI Score at Week 22 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-171.52","spread":"82.56"},{"groupId":"OG001","value":"-159.13","spread":"88.94"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI Score at Week 24 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-165.06","spread":"90.54"},{"groupId":"OG001","value":"-160.44","spread":"76.11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI Score at Week 26 in the Randomized Maintenance Phase","description":"The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-176.85","spread":"80.44"},{"groupId":"OG001","value":"-168.59","spread":"77.03"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to Loss of Response (CDAI Score > 150 and Minimum Increase in CDAI of 70) After Week 6","description":"Median time to loss of response in the maintenance period (from Kaplan-Meier analysis); range is time of first event to time of last event. Loss of response is defined as both a CDAI score \\> 150 points and a minimum increase in CDAI of 70 points versus Week 6 at two consecutive visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"125","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Remission is defined as CDAI score ≤ 150.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Remission is defined as CDAI score ≤ 150.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Remission is defined as CDAI score ≤ 150.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Remission is defined as CDAI score ≤ 150.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Remission is defined as CDAI score ≤ 150.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Remission is defined as CDAI score ≤ 150.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Remission is defined as CDAI score ≤ 150.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Remission is defined as CDAI score ≤ 150.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Remission is defined as CDAI score ≤ 150.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.","description":"Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"C - Reactive Protein (CRP) Level at Baseline (Week 0) of the Induction Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Week 2 of the Induction Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Week 4 of the Induction Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Week 6 of the Induction Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Week 8 in the Randomized Maintenance Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Week 10 in the Randomized Maintenance Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Week 12 in the Randomized Maintenance Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Week 14 in the Randomized Maintenance Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Week 16 in the Randomized Maintenance Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Week 18 in the Randomized Maintenance Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Week 20 in the Randomized Maintenance Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Week 22 in the Randomized Maintenance Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"13.0","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Week 24 in the Randomized Maintenance Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Week 26 in the Randomized Maintenance Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]}]},{"type":"SECONDARY","title":"CRP Level at Endpoint (Last Visit) in the Randomized Maintenance Phase","description":"High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L. Endpoint is the visit when the last observation was taken, either at week 26 or at a visit before in case of early dropout.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":187},"commonTop":["Headache","Nausea","Nasopharyngitis","Pyrexia","Arthralgia"]}}}